Volume: Issue: 12

1. Comments on:Benefits and risks of bisphosphonate therapy for osteoporosis Page:951—952
2. Benefits and risks of bisphosphonate therapy for osteoporosis Page:953—955
3. Effect of four different anti-osteoporosis agents on the expression of matrix gla protein in primary osteoblasts of SD rat Page:956—961
4. Osteoblast is necessary for IGF-I to promote bone resorption by osteoclast Page:962—966
5. A preliminary study on the influence of low-iron environment on serum osteocalcin and bone micro-structure in ovariectomized mice Page:967—971
6. Effect of metformin on proliferation and related genes expression of human osteoblast MG63 under high glucose Page:972—974
7. Association of peripheral white blood cell count with carotid intimal-medial thickness in middle-aged and elderly Chinese of suburban area of Shanghai Page:975—978
8. Approach to the patient of hyperthyroidism with myasthenia gravis Page:1020—1022
9. Efficacy and safety of glimepiride as initial treatment in newly-diagnosed patients with type 2 diabetes mellitus : sub-group analysis of GREAT study Page:979—983
10. Significance of adiponectin in the risk of coronary lesions in patients with impaired glucose regulation Page:984—988
11. SNPs in the SCGB3A2 promoter are associated with susceptibility to Graves' disease Page:989—993
12. Protective role of ERp46 in palmitic acid-induced endoplasmic reticulum stress Page:1012—1015
13. Significance of insulin tolerance test in the diagnosis of adult growth hormone deficiency Page:994—997
14. An epidemiological analysis of pituitary apoplexy Page:998—1000
15. Clinical characteristics of idiopathic hypogonadotropic hypogonadism in females: report of 16 cases Page:1001—1004
16. Effect of thyroidal motilin on gastric motility and central modulation in rat thyroid Page:1005—1011
17. Effect of globular domain of adiponectin on glucose metabolism and insulin signal transduction in insulin resistant model adipocytes Page:1016—1019
18. Development of FRAX in predicting fracture risk Page:1029—1032
19. Combination therapy of DPP-4 inhibitor and metformin: Rationality and its evidence Page:1033—1035